+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ribavirin treatment of the acquired immunodeficiency syndrome aids and the acquired immunodeficiency syndrome related complex arc a phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation



Ribavirin treatment of the acquired immunodeficiency syndrome aids and the acquired immunodeficiency syndrome related complex arc a phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation



Annals of Internal Medicine 107(5): 664-674



To assess safety, tolerance, and the clinical and laboratory effects of oral ribavirin in patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Three uncontrolled phase I trials of increasing duration: 14 days, 8 weeks, and 12 months. Outpatient clinic of a university-referral hospital. All patients were antibody-positive for the human immunodeficiency virus (HIV) by radioimmunoprecipitation assay, all had recovered from Pneumocystis carinii pneumonia, and none had Kaposi sarcoma at entry. Nine of ten patients with AIDS had less than 100 CD4+ lymphocytes/mm3 at entry and all patients with the AIDS-related complex had fewer than 200 CD4+ lymphocytes/mm3. Five patients with AIDS and five with the AIDS-related complex entered the 14-day trial. All but two patients with AIDS went on to the 8-week trial, along with seven additional patients with AIDS. Five surviving patients with AIDS and 3 patients with the AIDS-related complex went on to the 1-year study. Oral ribavirin, 1200 mg twice daily for 3 days was given, followed by 300 mg twice daily for 11 days. During an 8-week trial, a loading dose of oral ribavirin was administered for 3 days, followed by a dose of 300 mg twice daily for 8 weeks. Prolonged regimen of a 3-day loading dose was given, followed by a dose of 300 mg twice daily for 1 year. Ribavirin treatment was well tolerated, with anemia requiring transfusion in one of the ten patients with AIDS receiving the drug for 8 weeks; no other significant toxicity occurred. Six of the nine patients initially positive for HIV-1 in blood became negative during ribavirin treatment. Six of nine patients with AIDS had a twofold improvement in lymphoproliferative response to at least one lectin with ribavirin treatment. Mean survival from first episode to P. carinii pneumonia was 17.3 months in patients with AIDS receiving 9 weeks of ribavirin and 21.2 months in patients with AIDS receiving prolonged treatment. Oral ribavirin, 600 mg daily, was well tolerated and safe in the patients with severe AIDS and the AIDS-related complex. Ribavirin therapy merits extensive evaluation in a multicenter controlled trial to assess its efficacy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006342926

Download citation: RISBibTeXText

PMID: 3662279


Related references

Distribution of the level of antibody to acquired immunodeficiency syndrome associated virus in sera from acquired immunodeficiency syndrome related complex and japanese hemophiliacs infected with acquired immunodeficiency syndrome associated virus. Microbiology & Immunology 29(11): 1083-1088, 1985

Frequent transmission of human t cell leukemia lymphotropic virus iii among spouses of patients with acquired immunodeficiency syndrome related complex and acquired immunodeficiency syndrome. Journal of the American Medical Association 253(11): 1571-1573, 1985

Administration of 3' azido 3' deoxythymidine an inhibitor of human t lymphotropic virus iii lymphadenopathy associated virus replication to patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome related complex. Lancet 1(8481): 575-580, 1986

Medical Association of Georgia's 1987 report on human immunodeficiency virus. AIDS related complex and acquired immunodeficiency syndrome. Journal of the Medical Association of Georgia 77(1): 41-49, 1988

Occupational therapy creating possibilities for adults with human immunodeficiency virus infection aids related complex and acquired immunodeficiency syndrome. Occupational Therapy in Health Care 7(2-4): 125-138, 1990

Correlation between Lymphocyte CD4 Count, Treatment Duration, Opportunistic Infection and Cognitive Function in Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS) Patients. Open Access Macedonian Journal of Medical Sciences 6(4): 643-647, 2018

Antibody to human lymphotropic virus type III: immunologic status of homosexual contacts of patients with the acquired immunodeficiency syndrome and the acquired immunodeficiency-related complex. Sexually Transmitted Diseases 14(1): 44-47, 1987

Multimodality evoked potentials in acquired immunodeficiency syndrome aids and in acquired immunodeficiency syndrome related complex arc. Electroencephalography & Clinical Neurophysiology 66(5): S66, 1987

Hepatitis b virus dna sequences in lymphoid cells from patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome related complex. Science 229(4713): 561-563, 1985

Defective regulation of epstein barr virus in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome related complex. Journal of Allergy & Clinical Immunology 77(1 Part 2): 127, 1986

Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome (AIDS). Annals of Internal Medicine 109(9): 718-721, 1988

Pulmonary complications in acquired immunodeficiency syndrome (AIDS) and syndromes related to human immunodeficiency virus (HIV) infection. Giornale di Clinica Medica 69(12): 755-765, 1988

Acquired Immunodeficiency Syndrome (Aids) Risk in Recent and Long-standing Human Immunodeficiency Virus Type 1 (Hiv-1)-infected Patients with Similar Cd4 Lymphocyte Counts. American Journal of Epidemiology 138(10): 870-878, 1993

Complement activation is associated with the presence of specific human immunodeficiency virus hiv anti hiv immune complexes in patients with acquired immunodeficiency syndrome related complex of lymphadenopathy syndrome. Scandinavian Journal of Immunology 30(3): 347-354, 1989

Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong. Hong Kong Medical Journal 12(2): 133-140, 2006